Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.17)
# 1,093
Out of 5,090 analysts
106
Total ratings
38.38%
Success rate
16.65%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAVA Cassava Sciences | Initiates: Buy | $8 | $3.19 | +150.78% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $2.07 | +3,088.41% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.26 | +4,450.63% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $2.39 | +611.30% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $4.01 | +174.31% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $80.38 | -37.80% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.46 | +1,064.38% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $220 | $3.90 | +5,541.03% | 1 | Aug 19, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.73 | +709.25% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $4.55 | +1,372.53% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $13.43 | +220.18% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.02 | +199.00% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.20 | +525.00% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $4.32 | +247.22% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $12.35 | +70.04% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $5.82 | +552.92% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.13 | +3,439.82% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.23 | +702.57% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $5.99 | +1,803.17% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.77 | +3,366.20% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $14.89 | +121.63% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $23.63 | +69.28% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.11 | +3,233.33% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $8.78 | +264.46% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $7.13 | +979.94% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.24 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $61.44 | -18.62% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $4.70 | +602.13% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.89 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $10.85 | +139.63% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $234.13 | -88.04% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $4.88 | +17,335.90% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $12.58 | +66.93% | 2 | Jul 12, 2017 |
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $3.19
Upside: +150.78%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $2.07
Upside: +3,088.41%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.26
Upside: +4,450.63%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $2.39
Upside: +611.30%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $4.01
Upside: +174.31%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $80.38
Upside: -37.80%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.46
Upside: +1,064.38%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $220
Current: $3.90
Upside: +5,541.03%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.73
Upside: +709.25%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $4.55
Upside: +1,372.53%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $13.43
Upside: +220.18%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.02
Upside: +199.00%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.20
Upside: +525.00%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $4.32
Upside: +247.22%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $12.35
Upside: +70.04%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $5.82
Upside: +552.92%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $1.13
Upside: +3,439.82%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $6.23
Upside: +702.57%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $5.99
Upside: +1,803.17%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.77
Upside: +3,366.20%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $14.89
Upside: +121.63%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $23.63
Upside: +69.28%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.11
Upside: +3,233.33%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $8.78
Upside: +264.46%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $7.13
Upside: +979.94%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.24
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $61.44
Upside: -18.62%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $4.70
Upside: +602.13%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $10.89
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $10.85
Upside: +139.63%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $234.13
Upside: -88.04%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $4.88
Upside: +17,335.90%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $12.58
Upside: +66.93%